Overview
PNC-27 is a synthetic p53-derived peptide designed from the MDM2/HDM-2-binding region of the tumor suppressor p53 and linked to a membrane-residency or cell-penetrating sequence. It is researched for selective cytotoxicity against cancer cells, especially through interactions with membrane-associated HDM-2. It is not an approved cancer treatment.
Unlike therapies that aim to restore nuclear p53 transcriptional activity, PNC-27 is proposed to act at the cancer cell membrane. Studies from the Michl/Sarafraz-Yazdi research line suggest that PNC-27 binds HDM-2 expressed on cancer cell membranes, forms pores, disrupts membranes, and causes rapid necrotic cell death while sparing some untransformed cells in experimental systems.
PNC-27 is not FDA-approved, has no established human dosing, and should never replace oncology care. Cancer peptides are high-stakes research compounds; self-treatment risks delaying surgery, radiation, chemotherapy, immunotherapy, targeted therapy, or palliative care that has evidence. Any human use outside a registered clinical protocol is medically unsupported.
This guide explains the mechanism without hype, covers why preclinical selectivity does not equal clinical efficacy, reviews safety unknowns, and gives users the clearest practical message: PNC-27 belongs in controlled cancer research, not do-it-yourself treatment.
Quick facts
- Mechanism
- p53-derived peptide targeting membrane-associated HDM-2
- Primary use
- Preclinical anticancer research
- Evidence
- limited
- FDA
- Not approved
- Route
- Research injection or cell-culture use
- Typical results
- Cancer-cell killing in preclinical models only
Chemical information
PNC-27 is a large synthetic peptide with molecular mass 4031.73 g/mol and formula C188H292N52O44S. It combines a p53-derived HDM-2-binding region with a membrane-active peptide segment.
How PNC-27 works
PNC-27 contains an amino-terminal p53 sequence that can interact with HDM-2/MDM2-associated structures plus a membrane-active segment. The leading hypothesis is that cancer cells expressing HDM-2 on the plasma membrane bind PNC-27, allowing the peptide to insert into or disrupt the membrane and trigger necrotic death. This is preclinical research, not validated clinical oncology.
PNC-27 emerged from work designing p53-derived peptides that selectively kill transformed cells. The peptide is often discussed alongside PNC-28, a related p53-derived construct. In vitro studies reported rapid lysis of cancer cells and relative sparing of normal cells, suggesting a membrane-level vulnerability linked to HDM-2 expression.
Structural work suggested that PNC-27 adopts a conformation compatible with HDM-2 binding. Later studies extended the model to membrane-bound HDM-2 and mitochondrial disruption. The appeal is clear: a peptide that kills malignant cells independently of intracellular p53 status would be valuable. The limitation is equally clear: most evidence remains cell and animal research.
Cancer biology is heterogeneous. HDM-2 expression, membrane localization, tumor penetration, immune effects, peptide stability, off-target membrane activity, and pharmacokinetics all matter in humans. Without controlled trials, claims about tumor response, survival, or safety cannot be supported.
- p53-derived sequence: Built from the HDM-2-binding region of p53
- Membrane mechanism: Proposed to disrupt cancer cell membranes rather than restore nuclear p53
- HDM-2 association: Selectivity hypothesis depends on cancer cell surface HDM-2 expression
- Necrotic cell death: Studies describe rapid lysis and pore-like membrane disruption
- Preclinical stage: No FDA-approved indication or dosing exists
- Oncology caution: Should not replace evidence-based cancer treatment
Pharmacokinetics
No reliable human pharmacokinetic data define PNC-27 half-life, tumor penetration, systemic exposure, or dosing. Preclinical cytotoxicity should not be used to infer human dose or schedule.
| Parameter | Value | Significance |
|---|---|---|
| Human half-life | Not established | No clinical dosing interval |
| Tumor distribution | Not established in humans | Cell killing does not prove tumor penetration |
| Metabolism | Likely proteolytic degradation | Expected for peptides but unquantified |
| Route | Preclinical injection/cell culture | No approved human route |
| Therapeutic window | Unknown | Selectivity needs clinical confirmation |
| Monitoring | Oncology trial endpoints | Tumor imaging and safety labs would be required |
Dosing & administration
There is no approved PNC-27 dose. Any vendor protocol for human cancer use should be considered unsupported unless it is part of an ethically approved clinical trial.
Preclinical concentrations cannot be converted safely into human dosing by simple body-weight math. Cancer peptides require formulation, sterility, pharmacology, toxicology, and tumor exposure data before human dosing is rational.
People with cancer should discuss any interest in investigational peptides with their oncologist. The safest path is a registered clinical trial, not self-injection of research material.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
PNC-27 is an investigational anticancer peptide. Because cancer care is high-stakes, the absence of clinical proof is itself a major safety issue. It should not be used outside appropriate research oversight.
Common
- • Injection site irritation in experimental contexts
- • Flu-like symptoms are theoretically possible
- • Pain or inflammation at administration site
- • Nausea or fatigue are possible but not well characterized
- • Unknown immune reactions
- • Product-related contamination risk
Serious / potential risks
- • Unknown human toxicity profile
- • Potential off-target membrane effects
- • Immune or allergic reactions
- • Delayed cancer treatment if self-administered
- • Sterility and endotoxin risks from unregulated peptide sources
Drug interactions
Formal interaction data do not exist; oncology interactions would require trial-level evaluation.
| Medication | Interaction | Recommendation |
|---|---|---|
| Chemotherapy | Unknown additive toxicity or scheduling effects | Do not combine outside oncology oversight |
| Immunotherapy | Unknown immune and inflammatory consequences | Avoid unsupervised use |
| Anticoagulants | Injection and tumor necrosis risks are unknown | Medical supervision required |
| High-dose steroids | May alter immune response and cancer symptoms | Do not self-stack |
| Other anticancer peptides | Unknown overlapping toxicity | Use only in formal research |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research peptide suppliers | Variable high-cost custom peptide | Human use is not approved |
| Academic research | Grant or lab-funded | Requires purity, sterility, and assay validation |
| Clinical oncology care | Insurance and treatment dependent | Do not divert funds from evidence-based care |
The bottom line
PNC-27 is scientifically interesting because it targets a membrane-associated cancer vulnerability in preclinical models. It is not a proven cancer treatment, has no approved dosing, and should remain in controlled research settings unless clinical trials establish safety and benefit.
Best for
- • Cancer biology researchers
- • Preclinical peptide cytotoxicity studies
- • MDM2/HDM-2 membrane mechanism research
- • Formal translational oncology programs
Not for
- • DIY cancer treatment
- • Replacing oncology care
- • Use from unverified peptide vendors
- • Pregnancy or breastfeeding
Related compounds
Pancragen
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Phenibut
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Phenibut FAA
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Phenylpiracetam
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Frequently asked questions
References
- [1] Kanovsky M, Raffo A, Drew L, et al.. Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proceedings of the National Academy of Sciences of the United States of America (2001). doi: 10.1073/pnas.211280698
- [2] Do TN, Rosal RV, Drew L, et al.. Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. Oncogene (2003). doi: 10.1038/sj.onc.1206237
- [3] Sarafraz-Yazdi E, Bowne WB, Adler V, et al.. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proceedings of the National Academy of Sciences of the United States of America (2010). doi: 10.1073/pnas.0909364107
- [4] Ray A, Patel M, Shah R, et al.. The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line. Annals of Clinical and Laboratory Science (2014). PMID: 25117093
- [5] Ray A, Qian S, Mendez O, et al.. Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes. International Journal of Molecular Sciences (2024). PMID: 38802154
- [6] Vassilev LT. MDM2 inhibitors for cancer therapy. Trends in Molecular Medicine (2007). doi: 10.1016/j.molmed.2007.03.002 PMID: 17481929